SLC6A4 and depressive symptom measurement: For instance, Kang et al. reported that higher SLC6A4 promoter methylation status was significantly associated with adverse life events as well as worse clinical presentation of depression, and they suggested that SLC6A4 methylation status could serve as a marker for childhood adversities and as a clinical biomarker for specific presentations of depression [24].